JNJ - Another 14M J&J vaccine doses from Emergent plant authorized by FDA - Reuters

Tasos Katopodis/Getty Images News The FDA has given the OK for Johnson & Johnson (JNJ) to distribute another 14M doses of its COVID-19 vaccine produced at an Emergent BioSolutions (EBS) Baltimore facility, Reuters reported. Nearly all of the doses that have been authorized to date are expected to be shipped overseas. Doses have been sitting at the Emergent plant for some time after production was halted following a manufacturing mix-up in late March and an FDA inspection in April that found multiple deficiencies. The FDA said it was still not ready to give the OK for the plant to resume making the J&J vaccine. J&J shares closed today down 0.5% to $164.49, and Emergent shares closed down 0.4% to $61.57.

For further details see:

Another 14M J&J vaccine doses from Emergent plant authorized by FDA - Reuters